The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Abstract
Tumor-associated mutants of the p53 tumor suppressor protein exert biological activities compatible with an oncogenic gain of function. To explore the underlying molecular mechanism, we performed microarray analysis, comparing p53-null cells to mutant p53-expressing cells. One of the genes up-regulated in the presence of mutant p53 was EGR1, a transcription factor implicated in growth control, apoptosis, and cancer. EGR1 induction by various types of stress is markedly augmented in cells expressing mutant p53. Moreover, chromatin immunoprecipitation analysis indicates that mutant p53 is physically associated with the EGR1 promoter. Functional assays indicate that induction of EGR1 by mutant p53 contributes to enhanced transformed properties and resistance to apoptosis. We propose that EGR1 is a significant contributor to mutant p53 gain of function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123 · cited 1×
“8C, the p53R175H protein did not bind to a plasmid carrying the VEGF promoter while exhibiting good interaction with the CD95/Fas promoter, which was recently found to be a target for binding and transcriptional repression by mutant p53 (29).”
Self-citation
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…Formation V143A BEAS-2B stable/transient Gerwin et al., 1992 V143A, R175H, R248W, R273H H1299 stable/transient Kalo et al., 2012; Liu et al., 2011; Weisz et al., 2004 V143A, Y163C, R175H, L194R, R273H, D281G, R282W 10(3) stable/transient Scian et al., 2004a G144P, R158H, Y163N, H168Y, V173L,…”
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Self-citationMutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Self-citationTumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Metadata
- Authors
- Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V.
- Venue
- Cancer Research
- Published
- 2004-11-15
- Volume
- 64
- Issue
- 22
- Pages
- 8318-8327
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2105781930
- Cited by
- 130
- References
- 1
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-1145
- The paper
- Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004). Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-1145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.